Skip to main content

People in the News: Michael Powell, Ed Mathers, Elaine Jones, Tim Freeborn

Premium

Mirna Therapeutics has appointed a number of new board members following its recent Series C financing round (see related story, this issue).

Joining the board are Michael Powell, a general partner at Sofinnova Ventures, and Ed Mathers, a partner at New Enterprise Associates.

New additions to the board of directors also include Elaine Jones, executive director for venture capital/worldwide business development at Pfizer.


Silence Therapeutics has named Tim Freeborn as its finance director.

Freeborn joins Silence from Xcap Securities, where he was head of research.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.